Stock Movers

Today's biggest winners and losers in the stock market, a look at the notable movers:
On this episode of Stock Movers:

-Moderna (MRNA) shares surged, delivering a $5.5 billion blow to short sellers who had bet that the vaccine maker's slump would continue. The company's stock price soared 177% after it said its personalized cancer vaccine helped reduce the recurrence of melanoma in a late-stage trial. The jump generated paper losses of about $5.5 billion for short sellers, bringing mark-to-market losses to roughly $7.7 billion this year, according to data from S3 Partners LLC.

- SK Hynix (KS) unveiled plans to buy back 40 trillion won of shares and return more profits to investors, moving to stabilize its shares after they fell more than 50% in two months. The memory chipmaker will buy back as many as 24 million shares between Aug. 20 and Nov. 19 and cancel them, and raised its shareholder return pledge to more than 50% of cumulative free cash flow from 2025 to 2027. SK Hynix’s buyback plan is partly aimed at appeasing Korean retail investors who were upset by the company’s decision to issue new shares for its US listing, rather than through existing treasury stock, which diluted their local holdings.

- Estée Lauder (EL) shares jumped after its results beat estimates and ended a run of three straight declines in annual revenue. The company reported revenue of $3.6 billion in its fiscal fourth quarter and adjusted earnings per share of $0.39, which topped expectations. The company reaffirmed guidance for organic net sales growth and raised guidance on its adjusted operating margin, with analysts saying a steady recovery is underway.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:

Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Isabelle Lee, Carol Massar and Emily Graffeo

- Moderna (MRNA) shares surged, delivering a $5.5 billion blow to short sellers who had bet that the vaccine maker's slump would continue. The company's stock price soared 177% after it said its personalized cancer vaccine helped reduce the recurrence of melanoma in a late-stage trial. The jump generated paper losses of about $5.5 billion for short sellers, bringing mark-to-market losses to roughly $7.7 billion this year, according to data from S3 Partners LLC.

- Estée Lauder (EL) shares jumped after its results beat estimates and ended a run of three straight declines in annual revenue. The company reported revenue of $3.6 billion in its fiscal fourth quarter and adjusted earnings per share of $0.39, which topped expectations. The company reaffirmed guidance for organic net sales growth and raised guidance on its adjusted operating margin, with analysts saying a steady recovery is underway.

- TJ Maxx (TJX) shares fall 0.84% in Wednesday trading after the clothing retailer reported second-quarter comparable sales for its Marmaxx segment, which includes TJ Maxx and Marshalls, that missed the average analyst estimate.
See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:

-SK Hynix ADRs rose. SK Hynix Inc. unveiled plans to buy back 40 trillion won ($29 billion) of shares and return more profits to investors, moving to stabilize its shares after they fell more than 50% in two months. The memory chipmaker said it will buy back as many as 24 million shares between Aug. 20 and Nov. 19 and cancel them, according to a regulatory filing Wednesday. It also raised its shareholder return pledge to more than 50% of cumulative free cash flow from 2025 to 2027, equivalent to about $170 billion, according to Bloomberg calculations.

-Moderna (MRNA) shares rise. A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone. The companies will discuss filing for approval with regulators and will present the data at an upcoming medical meeting, with Moderna Chief Executive Officer Stéphane Bancel saying the product could be approved as soon as 2027.

-Estee Lauder (EL) shares jumped after its results beat estimates and ended a run of three straight declines in annual revenue. The company reported revenue of $3.6 billion in its fiscal fourth quarter and organic sales growth accelerated to 5%. The company reaffirmed guidance for organic net sales growth of 3% to 5% in its current fiscal year, and raised guidance on its adjusted operating margin.
See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Moderna (MRNA) shares rise. A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone. The companies will discuss filing for approval with regulators and will present the data at an upcoming medical meeting, with Moderna Chief Executive Officer Stéphane Bancel saying the product could be approved as soon as 2027.
- La-Z Boy (LZB) shares tumble after the furniture maker’s forecast sales for the second quarter missed the average analyst estimate. KeyBanc Capital Markets analyst Bradley Thomas says the company “issued F2Q sales and implied EPS guidance below consensus, pressured in part by continued investments”
- Norfolk Southern Corp (NSC) climbs after a federal regulator resumed its review of Union Pacific’s bid for the rival. The Surface Transportation Board established a procedural schedule for public comment, with participants having until Sept. 4 to file a notice of intent to participate in the review process.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Shares of Moderna (MRNA) surged by a record 101% - the stock’s biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.’s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday.
- Shares of Estee Lauder (EL) rallied after the beauty company’s adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views.
- Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker’s forecast sales for the second quarter missed the average analyst estimate.
See omnystudio.com/listener for privacy information.